Bristol-Myers Squibb Company
) recently announced encouraging data on its oncology candidate
nivolumab from a phase I dose-ranging trial (study 004: n=86).
The study evaluated the safety and anti-tumor activity of
nivolumab in combination with Bristol-Myers' marketed skin-cancer
drug Yervoy (combined either concurrently or sequentially) for
treating patients suffering from advanced melanoma. The data was
published in the New England Journal of Medicine.
Data from the study revealed that 53% (9 out of 17) patients
treated with the combination of nivolumab and Yervoy
(concurrently) had confirmed objective responses. The patients
were treated with the same combination dosage as is being used in
the ongoing phase III study. The phase III study is also
evaluating the combination of nivolumab and Yervoy in advanced
Data from the phase I study also revealed at least an 80%
tumor shrinkage in each of the above nine patients within twelve
weeks. Furthermore, an estimated survival rate (52-week) of 82%
was observed across all concurrent groups. Bristol-Myers
presented the estimated survival data at the annual meeting of
the American Society of Clinical Oncology.
We believe that the encouraging data on nivolumab is good news
for Bristol-Myers as its pipeline must deliver to combat the loss
of revenues due to the genericization of Plavix. Plavix,
), went off patent in the US in May 2012. Moreover, the threat of
genericization looms over many other key drugs at
Bristol-Myers, a biopharmaceutical company, carries a Zacks
Rank # 3 (Hold).
Alexion Pharmaceuticals, Inc.
Cubist Pharmaceuticals, Inc.
) appear to be more attractive in the biopharma space with a
Zacks Rank #2 (Buy) each.
ALEXION PHARMA (ALXN): Free Stock Analysis
BRISTOL-MYERS (BMY): Free Stock Analysis
CUBIST PHARM (CBST): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.